Prognostic impact of prediabetic glycated hemoglobin levels in nondiabetic patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis

Figure 1 PRISMA flow chart of the screening process.

Figure 2 Forest plots comparing clinical outcomes between patients with abnormal and normal glycated hemoglobin levels. A: Long-term all-cause mortality with subgroup analysis; B: Major adverse cardiovascular events with subgroup analysis; C: Short-term all-cause mortality; D: Cardiac mortality.